PQA Summary from
Building Consensus on Measures for Plan-Pharmacy Agreements:
A Workshop to Develop a Roadmap for Standard Quality Measures
July 31- August 1, 2019

The Pharmacy Quality Alliance (PQA) hosted a two-day workshop with community pharmacy, specialty pharmacy, health plan and PBM stakeholders to build consensus on measures for plan-pharmacy agreements. Discussion focused primarily on measures that could be incorporated in value-based models in Medicare Part D.

Workshop participants reached consensus on prioritized measures that could be used in the short, near and long term. This consensus was informed by the practical deadlines for measure availability for upcoming Medicare Plan Years. To address these time-sensitive needs, PQA will:

1. Re-specify plan-level measures to the pharmacy-level of analysis and evaluate the appropriateness of these pharmacy-level measures for performance assessment; and
2. Create pharmacy-level measures de novo.

In addition to establishing workstreams for these measurement needs, PQA will continue to build consensus around the workshop’s conclusions. PQA will share the workshop’s results with its Board and members and ensure broader input from PQA members and other relevant stakeholders. This workshop summary is the first part of that effort, which will be complemented by webinars, meetings and engagements. PQA is committed to developing consensus-based measures that are patient-centered, focused on improving care and of value to both pharmacies and payers.

This summary document provides details on the workshop and includes six sections:

- Background on the Workshop
- Addressing the Question: Why Start Now?
- The Approach to a New Set of Measures: Timelines Mean Everything!
- General Consensus from the Workshop
- Approaches to Measures for Future Plan Years
- Points Raised for Consideration by Stakeholders

The workshop agenda is included as an appendix. Questions about the workshop and PQA’s continuing work to build consensus on measures for plan-pharmacy agreements should be directed to PQA’s Measure Development Team at MeasureDev@pqaalliance.org.
Background on the Workshop

PQA is a multi-stakeholder, consensus-based membership organization that was established in 2006 as a public-private partnership with the Centers for Medicare and Medicaid Services (CMS) shortly after the implementation of the Medicare Part D Prescription Drug Benefit. PQA’s initial purpose was to establish evidence-based, valid and reliable plan-level performance measures for the Part D program. Focused on medication safety, adherence and appropriate use, these measures assess the quality of health plans and the services they cover. PQA measures are among the many measures used in the Part D Star Ratings program for accountability and the Display and Patient Safety programs to monitor plan performance for quality improvement.

Community and specialty pharmacy providers have advocated for the development of a new standard set of measures that can be used in pharmacy-plan and pharmacy-PBM contracting. They seek a set of measures that have been assessed and tested specifically for pharmacy-level importance, reliability, validity, feasibility and usability. Appropriately, they want these pharmacy-level measures to be used, in lieu of plan-level measures, in agreements between plans and pharmacies. Measures used in accountability programs must be tested at the level of attribution before taking them from one setting and applying them to another.¹

As an experienced developer of quality measures for medication use and medication services and through its consensus-based process, PQA is the most appropriate entity to develop a new standard set of measures that can be used in plan-pharmacy agreements.

As a potential new set of measures is considered, several priorities jointly shared by pharmacy and plan stakeholders have emerged:

- There is a short-term opportunity for new measures to be used in Medicare Part D agreements, as well as longer-term opportunities for Medicare and other agreements.
- There is recognition that front-line pharmacists can provide clinical services beyond encouraging improved adherence to optimize patient outcomes, which include screening and monitoring for intermediate outcomes (e.g., blood pressure, hemoglobin A1c).
- Measures should be patient-centered and focused on improving care.
- There must be appropriately aligned incentives around quality measurement for all parties and appropriate use of measures in the marketplace.

PQA convened an in-person, invitational workshop, July 31-August 1, in Alexandria, Va., to inform the creation of a roadmap for a standard set of measures that would be appropriate for pharmacy-level accountability. See Appendix A for the workshop agenda. Forty-five individuals attended the workshop, including representatives of community pharmacy, specialty pharmacy, health plans and PBMs, PQA staff, and guests. Facilitated by Cliff Goodman, PhD, Senior Vice President of The Lewin Group, the workshop had three objectives:

1. Identify a measure set, which:
   a. establishes new paradigm for pharmacy-health plan/PBM collaboration for improved medication management and patient outcomes;
   b. pharmacy stakeholders stand ready to be accountable to; and
   c. health plans and PBMs also see value
2. Gain health plan and PBM insights and perspectives on measures proposed by pharmacy stakeholders, including recommendations to refine
3. Understand potential for adoption and use of proposed new standard measure set

Addressing the Question: Why Start Now?

Before summarizing the findings of the workshop, it is important to answer the question posed by several attendees during the workshop and prior to the workshop: “Why start now?” The answer is simple and two-fold:

First, quality measure development takes time.
The average development time of a de novo measure is 18-24 months. Respecifying existing measures that have been developed for one intended use and ensuring reliability and validity for a different use also takes time. PQA believes respecifying existing measures could be conducted in five months, if appropriate access to the right data sources from volunteer testers is made available.

Second, we cannot anticipate whether Congress or the Administration will act on proposals to require a new set of standard measures.
PQA, as a multi-stakeholder, consensus-based convener, would develop a new set of measures, starting within the next 30-45 days, if we received feedback that this new standard set of measures could be adopted in the marketplace on a voluntary basis. Absent a federal mandate, these measures could still play a meaningful role in measuring what matters in the Medicare Part D program, and in other value-based models outside of Medicare. This proactive, forward-looking approach was a critical mindset for the workshop.

The Approach to a New Set of Measures: Timelines Mean Everything!
PQA’s approach to convening this workshop was tied to identifying measures that could be used in the short, near and long term. These timeframes were identified and mapped to upcoming Medicare Plan Year contracting periods. For measures to be used in Plan Year 2021, PQA is working under the assumption that measures would be needed to be fully developed or fully respecified by December 2019 to be considered in value-based arrangements between plans and pharmacies.

Table 1 outlines the practical measure development timelines for the next three plan years and includes the types of measures that stakeholders could consider, recognizing the practical deadlines for measure availability.
Based on measure ideas shared by community and specialty pharmacy stakeholders, and additional research by PQA’s performance measurement team, PQA staff drafted a list of proposed measures for consideration and distributed to confirmed workshop participants for review in advance of the meeting. For the first day of the workshop, PQA invited community and specialty pharmacy representatives to vet the proposed lists and to suggest additional measures that could be developed for pharmacy-level accountability that would be appropriate to include in a standard measure set.

We also invited physicians that have been involved with PQA to share their insights, given their experience with performance measures as practicing physicians being measured and their roles within organizations including health systems, clinics, pharmacies and quality improvement organizations.

It is important for the measure set to have value for all parties engaging in plan-pharmacy and PBM-pharmacy arrangements; therefore, we invited health plan and PBM representatives to participate on the second day of the workshop. The discussions included a lively exchange of viewpoints and perspectives, balanced with the realities of programmatic frameworks of large payor programs, such as Medicare, to determine whether this path forward and the measures outlined for use in future plan year contracting resonated with all stakeholders.

### General Consensus from the Workshop

Participants broadly agreed that we need to get started by sharing the workshop’s findings with PQA’s Board and membership, socializing the findings with the staffs and constituencies of organizations that participated in the workshop, ensuring broader input from relevant stakeholders, and establishing appropriate workstreams to support continued progress. PQA will advance these four themes in the months ahead:
I. Get Started:
   a. **Share findings with PQA’s Board of Directors.** PQA will share this summary document with its Board of Directors and ensure that their questions, perspectives and strategic direction are taken into full account. PQA was pleased to have seven members of its Board participate in the workshop, including the Chair and several Executive Committee members. Additionally, there were representatives from other Board members’ organizations in attendance that participated actively in the dialogue on both days.
   b. **Share findings with PQA’s membership.** PQA will host an all-member webinar on Thursday, August 22, to share the consensus that was achieved at the workshop. We will encourage all PQA members among health plans, pharmacies and PBMs to attend this webinar and share their feedback.

II. Socialize the Findings
   a. PQA offered to join conference calls or webinars with organizations that attended the workshop to socialize the event’s consensus with their relevant staffs. PQA recognizes that the discussion impacts cross-functional teams within an organization as it relates to quality, clinical services, measurement, network administration, and plan-pharmacy agreements. These conversations will help PQA gain broader input and insights for its subsequent work.
   b. The offer to host these conference calls or webinars also extends to the associations that are members of PQA that have an important member constituency from which they need to gather input. If an association wants to host a webinar for their membership, PQA would be pleased to participate and receive additional input.

III. Ensure Broader Input
   a. PQA has a network of leadership contacts within health plan associations including America’s Health Insurance Plans, Alliance of Community Health Plans, Association for Community Affiliated Plans, Blue Cross Blue Shield Association, and others that we could engage to share the workshop’s consensus and gather their perspectives. Alternatively, we could also invite them to the August 22 all-member webinar as guests.

IV. Establish Appropriate Workstreams to Support Continued Progress
   a. At the workshop’s conclusion, it was recommended that PQA facilitate progress through two workstreams:
      i. Structure workstream
      ii. Pharmacy Measures workstream

As PQA is moving forward to respecify and test selected health plan measures as pharmacy measures, we are seeking volunteers to participate on each of these workstreams. All PQA members representing pharmacy, health plan and PBM stakeholders are welcome to volunteer for these workstreams.
Approaches to Measures for Future Plan Years

Based on the workshop’s consensus and in the interest of creating a standard set of measures that could be used in plan-pharmacy agreements, PQA will take two approaches to meet this need, which align with upcoming Medicare Plan Years:

Measures for Plan Year 2021 (to be completed by PQA by December 2019-January 2020)

- Re-specify plan-level measures to the pharmacy-level of analysis and evaluate the appropriateness of these pharmacy-level measures for performance assessment
  - PQA has developed, tested, and endorsed measures intended for health plan performance comparisons. Many of the PQA-endorsed health plan measures currently are used in Medicare quality programs, as well as other national-, regional- and state-level programs. To support alignment of measures across programs, and aligned with the interest of stakeholders that participated in the PQA-convened Consensus Workshop: Building a Roadmap for Standard Quality Measures, PQA plans to re-specify and test the following health plan measures as pharmacy measures:

  **Community Pharmacy**
  - Concurrent Use of Opioids and Benzodiazepines
  - Statin Use in Persons with Diabetes
  - Adherence: 3 Rates (RASA, DR, STA)
  - MTM Program Completion Rate for CMR
  - Polypharmacy: Use of Multiple Anticholinergics in Older Adults

  **Specialty Pharmacy**
  - Treatment of Chronic Hepatitis C: Completion of Therapy (HCV)
  - Adherence to Non-Infused Disease Modifying Agents Used to Treat Multiple Sclerosis (PDC-MS)
  - Adherence to Antiretrovirals (PDC-ARV)
  - Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA)

The re-specification process will include:
- Refining the narrative specifications of the measures to reflect pharmacy-level analysis
- Applying an attribution method to determine which individuals the pharmacy, or specialty pharmacy would be accountable for in the measures (i.e., the individuals that fall into the denominator for the respective pharmacy/specialty pharmacy)
- Using administrative claims data to assess feasibility, validity and reliability of the measures at the pharmacy-level of analysis
• Reviewing the new specifications and testing results with a technical expert panel

_The measures that prove to be feasible, valid and reliable would then be recommended for inclusion in a standard set of pharmacy-level measures for the intended use of pharmacy performance assessment and could be used within pharmacy-plan and pharmacy-PBM contracts for Medicare Part D._

**Measures for Plan Year 2022 and beyond (to be completed by December 2020-January 2021)**

• Create pharmacy-level measures de novo
  • Community pharmacy, specialty pharmacy, and health plan and PBM stakeholders also are interested in new measures that would reflect services provided by pharmacies (e.g., reporting Hemoglobin A1c values) and specialty pharmacies.

Those measures would go through the full PQA measure development process, including specification, testing and endorsement. The new pharmacy-level measures would be specified, tested and endorsed for the intended use of pharmacy performance assessment. Depending on what is being measured, the data sources could include claims data, pharmacy system data, lab data, patient-reported data, and others.

**Points Raised for Consideration by Stakeholders**

The workshop generated a collaborative and productive dialogue among pharmacy, health plan and PBM representatives on Day 2. The following points summarize important measurement opportunities and challenges to be considered in our continued work. These points will inform our workstreams, measure development and any additional efforts needed to advance pharmacy-level quality measurement.

• Alignment of incentives is critical. Pharmacy representatives prioritized the short-term measures for Plan Year 2021, due to their alignment with measures that health plans are held to by CMS in the Stars/Display program.
• New measures must be incorporated into value-based models in Medicare Part D. The alignment around financial incentives is as important as the alignment around measurement.
• Stakeholders were generally aligned on this new direction, recognizing that flexibility on timelines may be critical.
• Health plan stakeholders asked if other measures could be included, and if there is room for expansion—answer is yes.
• Health plans asked how pharmacies can help with the HEDIS measure, *Statin Therapy for Patients with Cardiovascular Disease*. Pharmacy representatives responded that currently when making calls to prescribers, the lack of complete information
(specifically, the lack of patient diagnosis data at the point of care in a pharmacy) makes this measure challenging for pharmacists to impact.

- Question was raised around pharmacist-provided clinical services and the lack of ability to have this attributed to pharmacists/pharmacies in the HEDIS measurement set. Suggested action for follow-up includes a core group of health plans, together with community pharmacies, pursuing a meeting/dialogue with NCQA to see if supplemental data, provided by the pharmacy in an interoperable manner would be considered for attribution.

- If pharmacy data could be included in the HEDIS measurement supplemental data set, how can that be an opportunity for payors and pharmacies to align? It was noted that this action step should be taken in parallel with PQA respecifying these screening and monitoring types of measures for pharmacy accountability.

- Pharmacy stakeholders pointed out that there needs to be a runway, similar to the evolution in physician quality measurement (i.e., PQRS → meaningful use → MACRA), whereby pharmacies initially attest to performing the clinical service and then progress along a continuum for reporting, improvement, and outcomes (e.g., Hemoglobin A1c testing → HbA1c value reported → improvement in HbA1c → HbA1c at goal) – with improvement and outcomes included in arrangements where the pharmacy is accountable.

- Other areas for measure development that fell into a longer-term category was the role of the pharmacist in transitions of care, and the role of the pharmacist in behavioral healthcare (e.g., the administration of a PHQ-9 screening tool). It was reiterated in both cases, that data availability (e.g., timely notification of hospital discharge) would be critical for pharmacists/pharmacies to impact and for the measures to be meaningful.

- Measuring the Patient Experience at the Pharmacy Level: a great deal of conversation was held around the CAHPS Survey for Medicare beneficiaries and the fact that it could be beneficial to have pharmacy experience data built into the supplemental questions that could be added to CAHPS. This is an area for further exploration. Potential follow-on activity with a subgroup of experts to look more into this opportunity.

- Interoperability and diagnosis codes will be two critical factors to being able to successfully develop many of the future-looking measures that should come into play to truly re-imagine the collaborative roles pharmacists can have with their health plan and PBM counterparts.

- Stakeholders are aligned on PQA working on short-term respecified measures while in parallel with initiating development on longer term measures.
### APPENDIX A: WORKSHOP AGENDA

**Building Consensus on Measures for Plan-Pharmacy Agreements:**
*A Workshop to Develop a Roadmap for Standard Quality Measures*
*July 31–August 1, 2019*
*Alexandrian Hotel, 480 King Street, Alexandria, VA 22314*

**Day 1 (Wednesday, July 31, 2019)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:30 a.m.</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td>8:30-9:00 a.m.</td>
<td>Welcome, Introductions, Acknowledgement and Review of Antitrust Statement, and Review of Workshop Objectives (Cliff Goodman, Lewin Group, and Laura Cranston, PQA)</td>
</tr>
<tr>
<td>9:00-10:00 a.m.</td>
<td>What Makes a Good Measure (Karen Johnson, NQF)</td>
</tr>
<tr>
<td>10:00-10:30 a.m.</td>
<td>Approach to Creating a Standard Set of Measures (Cliff Goodman, Lewin Group, and Lynn Pezzullo, PQA)</td>
</tr>
<tr>
<td>10:30-10:45 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>10:45 a.m.-12:00 p.m.</td>
<td>Discussion of Measure Ideas for a Standard Set for Plan-Pharmacy Agreements (Lisa Hines and Lynn Pezzullo, PQA)</td>
</tr>
<tr>
<td>12:00-1:00 p.m.</td>
<td>Lunch</td>
</tr>
<tr>
<td>1:00-3:15 p.m.</td>
<td>Breakout Sessions (Community and Specialty Pharmacy Prioritize Measures)</td>
</tr>
<tr>
<td>3:15-3:30 p.m.</td>
<td>Break</td>
</tr>
<tr>
<td>3:30-4:30 p.m.</td>
<td>Breakout Session Report Outs and Next Steps (Cliff Goodman, Lewin Group, and Lynn Pezzullo, PQA)</td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td>Adjourn</td>
</tr>
<tr>
<td>5:00-6:30 p.m.</td>
<td>Networking Reception</td>
</tr>
</tbody>
</table>

**Day 2 (Thursday, August 1, 2019)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:30 a.m.</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td>8:30-9:00 a.m.</td>
<td>Welcome, Introductions, Acknowledgement and Review of Antitrust Statement, and Review of Workshop Objectives (Cliff Goodman, Lewin Group, and Laura Cranston, PQA)</td>
</tr>
<tr>
<td>9:00-10:00 a.m.</td>
<td>Gaining Input and Feedback on the Measures Prioritized by Community Pharmacy and Specialty Pharmacy (Cliff Goodman, Lewin Group)</td>
</tr>
<tr>
<td>10:00-10:15 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>10:15-11:15 a.m.</td>
<td>Gaining Input and Feedback on the Measures Prioritized by Community Pharmacy and Specialty Pharmacy (cont’d) (Cliff Goodman, Lewin Group)</td>
</tr>
<tr>
<td>11:15 a.m.-12:00 p.m.</td>
<td>Defining Next Steps, Timelines, and Commitments from PQA and from Stakeholders (Cliff Goodman, Lewin Group, and Laura Cranston and Lynn Pezzullo, PQA)</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>